Mentioned in ?
References in periodicals archive ?
A 456 per cent surge in the Nasdaq Biotechnology Index has driven its price-sales ratio to an 11-year high of 9.
The company is acquired at a price-earnings ratio of 5 and price-sales ratio of 1.